Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
UK Startups and Innovation
13MAY

VCTs hit £917.7m record, brace for 65% fall

4 min read
20:05UTC

Retail investors poured a third-highest-ever tally into Venture Capital Trusts ahead of a tax cliff on 6 April. The precedent from 2006 suggests the follow-on year lands near £320m.

TechnologyDeveloping
Key takeaway

A retail-funded seed tier is collapsing exactly as state growth capital expands, with no bridge between them.

Wealth Club reported on 14 April 2026 that Venture Capital Trusts raised £917.7m in 2025/26, the third-highest year on record including dividend reinvestment. Albion VCTs took £90m, British Smaller Companies VCTs £85m, and Octopus Apollo VCT £82.7m. 1 VCTs are listed investment trusts that give UK retail investors income-tax relief on stakes in small, unquoted companies; the vehicle is the closest thing Britain has to a retail-funded seed market.

HM Treasury telegraphed a cut in VCT income-tax relief in the November 2025 Budget, from 30% to 20%, effective 6 April 2026 , and retail money rushed in ahead of the deadline. The last time HM Treasury cut VCT relief, from 40% to 30% in 2006/07, annual fundraising fell 65% and took sixteen years to recover. Applied to £917.7m, that precedent puts the 2026/27 number near £320m, roughly £600m of early-stage capital that will not exist.

A Focaldata survey of investors and founders puts the mechanism in numbers: 43.5% of current VCT investors say they will invest less at the new 20% relief, and 41.6% say they will stop entirely. Of founders surveyed, 91% said their business would be smaller without VCT capital. 2 The 2006 precedent, the intention survey, and the scheme's maths all point the same way.

The gap this opens sits between £250,000 and £2m, historically the ticket range VCT money filled. Nothing in the state's new £8bn-plus of capital instruments reaches that range. The British Business Bank's direct-investment mandate starts at £5m minimum; SAIU offers £1m to £20m per firm; grant award counts are already at a ten-year low even as the average grant rises. For founders raising below £2m, the state has added growth-stage tonnage while letting the retail-funded rung of the ladder rust. The 2026/27 Q1 VCT figures, due in summer, are the first evidence point that will settle whether 65% is the right projection or whether the shift to EIS absorbs more than analysts expect.

Deep Analysis

In plain English

Venture Capital Trusts (VCTs) are a way for ordinary investors to back small British companies and get a tax break in return; they used to get 30p back for every £1 invested via a tax refund, and that made the risk worthwhile. The government cut that rebate to 20p from 6 April 2026. Surveys suggest most people who bought VCTs will now invest less or stop entirely. That matters because VCTs have historically been the main source of small cheques between £250,000 and £2m for startup founders who are too small for the big investment funds and too big for a bank loan. A projected £600m per year gap is now opening up at exactly that funding level.

Deep Analysis
Root Causes

HM Treasury's 2025 Autumn Statement fiscal scorecard listed VCT income tax relief as a £700m annual Exchequer cost, making it a visible target for a Chancellor under OBR deficit-reduction pressure; the downstream seed-capital effect was not modelled in the OBR's published costings, which assessed only the direct tax expenditure without netting against the revenue generated by companies VCTs fund.

The 2022-2023 gilt crisis raised the risk-free return available to retail investors from approximately 0.1% to 4.5%, materially increasing the opportunity cost of holding illiquid five-year VCT positions at the same absolute relief rate; the effective attraction of VCT relief had already been eroding before the April 2026 cut, which is why the Focaldata survey may overstate the cut's marginal impact.

What could happen next?
  • Consequence

    Smaller VCT managers without established track records; Wealth Club's Alex Davies specifically named this group; will face consolidation within 18 months as investors concentrate remaining allocations in top-three providers, reducing the diversity of early-stage investment mandates from approximately 25 active VCT managers today to perhaps 12-15 by 2027.

    Medium term · 0.7
  • Risk

    The 2026/27 Q1 VCT fundraising data, due from Wealth Club in approximately April 2027, will be the first hard test of the 65% projection; if it shows a decline greater than 65%, Chancellor Reeves will face parliamentary pressure to reinstate the 30% rate before the 2027 Autumn Statement.

    Medium term · 0.6
  • Consequence

    EIS will absorb some displaced VCT capital but at higher per-investor cost and lower average ticket size; expect EIS annual company subscriptions to rise 20-30% in 2026/27 as VCT-adjacent fund managers convert their retail investor bases to EIS-qualifying products.

    Short term · 0.65
First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

Wealth Club· 22 Apr 2026
Read original
Causes and effects
Different Perspectives
Australian Department of Defence (AUKUS AI for Acoustics partner)
Australian Department of Defence (AUKUS AI for Acoustics partner)
Rowden Technologies holds active AUKUS AI for Acoustics contracts with the UK, US, and Australian defence establishments. The NWF's £25m investment in Rowden on 13 May brings UK sovereign capital directly into a trilateral programme, which from Canberra's perspective places additional UK government skin-in-the-game on a programme Australia co-funds and co-develops.
Sofinnova Partners (European VC co-investor in Cytospire Series A)
Sofinnova Partners (European VC co-investor in Cytospire Series A)
Sofinnova participated alongside the BBB in Cytospire's oversubscribed £61m Series A on 5 May, demonstrating that the BBB's expanded direct mandate is attracting established European specialist biotech funds rather than replacing them. European VCs see the BBB's cornerstone position as a signal reducing UK biotech execution risk rather than crowding out private capital.
Temasek (Singapore sovereign co-investor in Isomorphic Series B)
Temasek (Singapore sovereign co-investor in Isomorphic Series B)
Singapore's Temasek co-invested alongside the UK's SAIU in Isomorphic's $2.1bn round, treating the same Alphabet-majority company as an acceptable sovereign co-investment target. Temasek's participation normalises the structure: multiple sovereign wealth funds backed the same round, strengthening the precedent that UK-headquartered Alphabet subsidiaries qualify for state investment.
Alphabet / Google (majority Isomorphic shareholder, Mountain View)
Alphabet / Google (majority Isomorphic shareholder, Mountain View)
Alphabet co-invested via GV and CapitalG in the same Isomorphic Series B round that received UK sovereign backing, placing US corporate capital and UK public capital in the same syndicate without any governance asymmetry. SAIU's minority stake validates Isomorphic's strategic value without constraining Alphabet's control over IP, geography, or exit decisions.
DSIT / Liz Kendall, Secretary of State for Science
DSIT / Liz Kendall, Secretary of State for Science
DSIT framed the Isomorphic investment as backing a British-founded and headquartered company advancing UK AI capability, and described the nine-day sovereign deployment sprint as evidence the government's industrial strategy is operational. The department has not addressed the ownership question, the absence of eligibility criteria, or the pace-versus-doctrine tension in the BBB mandate.
Beauhurst / UK startup data analysts
Beauhurst / UK startup data analysts
Five sub-£50m rounds closed in nine days with zero VCT-backed angel networks on any cap table, confirming the post-cut investor map is forming fast in the £4m–£40m band. The gap is structural: 36.7% of university spinouts raised below £500,000 in 2025, a tier neither the SAIU nor the BBB direct mandate touches.